First-line crizotinib versus pemetrexed-cisplatin or pemetrexed-carboplatin in patients (pts) with advanced ALK-positive non-squamous non-small cell lung cancer (NSCLC): results of a phase III study (PROFILE 1014) Meeting Abstract

Industry Collaboration International Collaboration

cited authors

  • Mok, Tony, Kim, Dong-Wan, Wu, Yi-Long, Solomon, Benjamin J., Nakagawa, Kazuhiko, Mekhail, Tarek, Felip, Enriqueta, Cappuzzo, Federico, Paolini, Jolanda, Usari, Tiziana, Tursi, Jennifer, Blackhall, Fiona Helen

authors

Publication Date

  • May 20, 2014

webpage

published in

category

volume

  • 32

issue

  • 15

WoS Citations

  • 2

WoS References

  • 0